Chagas Disease Clinical Trial
Official title:
Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy
The purpose of this study is to analyze the influence of polymorphisms of the genes CLDN-1 (Claudina-1), LGALS3 (Lectin galactoside-binding soluble 3), SOCS3 (Suppressor of cytokine signaling 3), IL-28B (interleukin-28B), CCL5 (Chemokine C-C ligand 5) in the determination of clinical forms and in the percentage of cardiac fibrosis in patients with Chagas disease.
The Chagas disease, in its chronic phase, can lead to the development of cardiac arrhythmias
and dilated cardiomyopathy, which can evolve to heart failure, causing great morbidity and
reduction on patient's quality of life. Some patients stay asymptomatic while others develop
the cardiac form of the disease (chronic chagasic cardiomyopathy), or other forms, like the
digestive (megacolon and megaesophagus) and the mixed form (cardiac and digestive).
The objective of this study is to analyze the association between single nucleotide
polymorphisms with the clinical forms and the amount of cardiac fibrosis in patients with
Chagas disease.
The polymorphisms will be analyzed by real time PCR (Polymerase Chain Reaction). The genes
whose polymorphisms will be analyzed are: galectin-3, SOCS-3, IL-28B, CLDN-1 and CCL5.
The patients shall be accompanied in the specialized outpatient clinics for Chagas disease -
Center of Biotechnology and Cell Therapy. They will be submitted to collection of blood
samples for biochemical analysis and cardiac magnetic resonance imaging.
;
Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01162967 -
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
|
Phase 2 | |
| Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
| Active, not recruiting |
NCT04024163 -
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
|
Phase 3 | |
| Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
| Completed |
NCT03892213 -
Pharmacokinetic Drug-Drug Interaction Study
|
Phase 1 | |
| Recruiting |
NCT00875173 -
Selenium Treatment and Chagasic Cardiopathy (STCC)
|
Phase 3 | |
| Recruiting |
NCT03704181 -
Colchicine for Patients With Chagas´ Disease( B1 Stage)
|
Phase 2 | |
| Active, not recruiting |
NCT03378661 -
BENDITA BEnznidazole New Doses Improved Treatment and Associations
|
Phase 2 | |
| Completed |
NCT01927224 -
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
|
Phase 1 | |
| Completed |
NCT01006486 -
Outcomes of an Anticoagulation Clinic in an University Hospital
|
Phase 4 | |
| Completed |
NCT00123916 -
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
|
Phase 3 | |
| Completed |
NCT02516293 -
Cardiac Rehabilitation in Chagas Heart Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT02517632 -
Physical Exercise Program in Chronic Chagas Heart Disease
|
Phase 3 | |
| Recruiting |
NCT02099903 -
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
|
N/A | |
| Completed |
NCT01874795 -
Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure
|
N/A | |
| Completed |
NCT01006473 -
Exercise Training in Chagas Cardiomyopathy
|
Phase 4 | |
| Completed |
NCT02386358 -
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
|
Phase 3 | |
| Not yet recruiting |
NCT05477953 -
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
|
||
| Recruiting |
NCT02295215 -
Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
|
N/A | |
| Completed |
NCT03350295 -
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
|
Phase 1 |